Seer, Inc. (SEER) Stock

Seer, Inc., a dynamic player in the life sciences sector, focuses on advancing and commercializing products aimed at unraveling the complexities of the proteome. The company specializes in developing the Proteograph Product Suite, a comprehensive offering that includes consumables, automated instrumentation, and software. This integrated solution empowers researchers to conduct proteomic studies crucial for therapeutic and diagnostic research, as well as clinical trials.

Seer aims to market its products primarily for research applications, catering to academic institutions, life sciences research laboratories, and biopharmaceutical and biotechnology companies. These solutions are intended for non-diagnostic and non-clinical purposes, supporting innovative discoveries across diverse scientific domains.

In pursuit of its mission, Seer has forged strategic collaborations, including partnerships with Discovery Life Sciences, LLC, and the esteemed Salk Institute for Biological Studies. These alliances underscore the company's commitment to leveraging collective expertise and resources to advance proteomic research.

Originally incorporated as Seer Biosciences, Inc., the company rebranded to Seer, Inc. in July 2018. Headquartered in Redwood City, California, Seer continues to drive innovation in proteomics, striving to unlock new insights that could potentially transform the understanding and treatment of complex diseases.